CN1814303A - Microcapsule for promoting bone regeneration and its use - Google Patents
Microcapsule for promoting bone regeneration and its use Download PDFInfo
- Publication number
- CN1814303A CN1814303A CN 200510110750 CN200510110750A CN1814303A CN 1814303 A CN1814303 A CN 1814303A CN 200510110750 CN200510110750 CN 200510110750 CN 200510110750 A CN200510110750 A CN 200510110750A CN 1814303 A CN1814303 A CN 1814303A
- Authority
- CN
- China
- Prior art keywords
- microcapsule
- cell
- gene
- stem cells
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 49
- 230000010478 bone regeneration Effects 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 13
- 238000012637 gene transfection Methods 0.000 claims abstract description 12
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 11
- 238000001890 transfection Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 8
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 32
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 22
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 12
- 239000000661 sodium alginate Substances 0.000 claims description 12
- 235000010413 sodium alginate Nutrition 0.000 claims description 12
- 229940005550 sodium alginate Drugs 0.000 claims description 12
- 239000000648 calcium alginate Substances 0.000 claims description 10
- 235000010410 calcium alginate Nutrition 0.000 claims description 10
- 229960002681 calcium alginate Drugs 0.000 claims description 10
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 9
- 239000003292 glue Substances 0.000 claims description 8
- 108010039918 Polylysine Proteins 0.000 claims description 6
- 229920000656 polylysine Polymers 0.000 claims description 6
- 108700023471 alginate-polylysine-alginate Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 3
- 230000034127 bone morphogenesis Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 abstract description 12
- 210000000988 bone and bone Anatomy 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 abstract description 4
- 230000003321 amplification Effects 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 230000011164 ossification Effects 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 11
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000867 polyelectrolyte Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
This invention relates to a stimulating bone regenerating micro capsule, the capsule is made as following method. (1) Recombination adenovirus carries bone form occurrence albumen. (2) Cultivation of mesenchyme stem cell between bone marrows. (3) Adenovirus carrier transfection bone marrows mesenchyme stem cell that carries osteogenesis gene. (4) microencapsulation of mesenchyme stem cell between bone marrows of bone form occurrence albumen gene transfection. Its advantages are that non-self body stem cell is allowed to use as target cell of gene transfection, so the time of amplification cultivation get from body stem cell. It is used for emergency patient, and can be filtrated out of body, so the quality of cell can be confirmed, and the application range of cell and gene curing can be extended.
Description
Technical field
The present invention is about a kind of microcapsule, especially in regard to a kind of microcapsule that promotes osteanagenesis.
Background technology
The gene therapy of osteanagenesis at present utilizes autologous stem cells as the gene transfection stem cell, as the bone morphogenesis protein-2 gene that utilizes adenovirus vector to carry, and the transfection autologous bone marrow mesenchymal stem cells is replanted defect to the marrow, promotes osteanagenesis.All achieve success on one's body at big toy at present.But present osteanagenesis gene therapy also has following shortcoming: (1) all utilizes the target cell of autogenous cell as gene transfection, because separation, cultivation, the amplification of cell need the long period, can't be used for the emergency case; Even for the patient who chooses date for operation, need patient at first to come institute to get bone marrow, treat that cell culture arrives requirement and (in our experience, obtains 10
7The cell 25 days left and right sides time of needs) come hospital again after, be difficult to be accepted by patient.Moreover individual stem cell population and quality exist than big-difference, is difficult to guarantee that each patient's of being cultivated cell all has vigor preferably.Quality and quantity as stem cell in old people's bone marrow is all poor than youngster, and the patient who suffers from systemic disease, metabolic disease and chemotherapy faces the problem of stem cell population deficiency, downgrade too.(2) as adopting the carrier of adenovirus as gene, adenovirus itself can be induced rejection, has limited genes of interest expression time in vivo.(3) as utilizing allosome or heterogenous cell as genetically modified target cell, need to use the general immunosuppressant, the immunologic function of human body there is certain infringement.
Summary of the invention
The object of the present invention is to provide:
(1) a kind of microcapsule that promotes osteanagenesis;
(2) microcapsule is used in preparation treatment osteopathia medicine.
The objective of the invention is to realize by following technical method:
(1) carries the recombinant adenovirus of bone morphogenetic protein gene, BMP-2cDNA fragment (being provided by ATCC) is inserted among the carrier PAC-CMV, constitute recombiant plasmid PAC-CMVBMP2, again with PAC-CMVBMP2 through behind the Xho I enzyme action with the big fragment of 5 type adenoviral genes behind Cla I enzyme action homologous recombination in 293 cells, form the recombinant adenovirus carry bone morphogenetic protein gene-2 gene.
(2) cultivation of rat bone marrow mesenchymal stem cells and Adenovirus Transfection are got body weight 120g left and right sides SD rat, the ketamine intraperitoneal anesthesia.Under the aseptic condition of strictness, isolate the bilateral femur, with its far and near end of rongeur amputation.Flush out myeloid tissue with 10ml alpha-MEM complete medium, be inoculated in the 100mm culture dish, every ware 10ml places 37 ℃, 5%CO
2Incubator is hatched.Later half amount was changed liquid in 3 days, changed liquid after 1 week fully, changed liquid later on weekly 2 times.On 14 days, attached cell almost 90% converged, and the exhaustion culture medium with PBS flushing 2 times, adds 1ml 0.05 trypsin and contains 0.02%EDTA), place 37 ℃, 5%CO
2Incubator was hatched 5 minutes, added 9ml low sugar a-MEM complete medium with the tryptic activity that neutralizes.Blow and beat cell gently with suction pipe and make and become single cell suspension, by the cultivation of going down to posterity in 1: 3, the cell of this moment claimed first passage cell.Carrying out the 2nd passage cell with method cultivates.After the 2nd passage cell nearly 90% converges, blot culture medium, every ware adds 4ml virus working solution and spends the night (MOI=100), or does not add processing, and hatching is spent the night.The viral working solution that exhausts, every ware add 10ml alpha-MEM complete medium (FCS is through hot deactivation) to be continued to cultivate.
(3) microencapsulation of the mesenchymal stem cells MSCs of BMP-2 gene transfection
The mesenchymal stem cells MSCs of BMP-2 gene transfection is suspended in 1.5% sodium alginate soln of filtration sterilization cell concentration 3 * 10 again
6/ ml.The cell suspending liquid of sodium alginate oozes by No. 7 blunt nosed pins of syringe pump, by large power high voltage pulse microcapsule preparing instrument (referring to utility model patent: microcapsule shaped device (patent No.: 00218100.2)), shear the drop that syringe pump oozes, and control its particle diameter.The sodium alginate Cell sap drops in gelation in the 100mM calcium chloride solution, forms calcium alginate cell glue pearl after about 5 minutes; After normal saline cleaning 2 times, calcium alginate cell glue pearl is suspended in the 0.05%-0.1% polylysine solution of filtration sterilization 5 minutes, polylysine and calcium alginate generation polyelectrolyte complex reaction film forming form embedding mesenchymal stem cells MSCs polylysine alginate microcapsule.The reuse normal saline cleans 2 times, immerses 0.15% sodium alginate soln afterwards about 5 minutes, forms another layer sodium alginate coat, cleans 2 times with normal saline, and with 55mM sodium citrate solution 20ml reaction 6 minutes, the core of microcapsule was liquefied then.After normal saline cleans, add culture medium, 37 ℃ of incubators are cultivated.
The present invention uses the ultimate principle of microencapsulation technology: utilize the chemical method embedding to transplant and use cell, form complete cyst membrane, i.e. microcapsule in the extracellular.Microcapsule has permselectivity, and hole on the film allows small-molecule substance such as nutrient substance to free in and out, but macromolecular substances such as antibody and immunocyte are blocked in outside the capsule.Microcapsule has been for its inside provides the microenvironment of an immunoprotection, make the cell heteroplastic transplantation in the microcapsule after, can avoid the attack of host's rejection, and at allosome survival justacrine therapeutic recombiant protein (general molecular weight is less than 100kD).Therefore, use the microencapsulation technology in cell transplantation, not only do not need to use immunosuppressant, also enlarged the source of transplantation donor, also bone is damaged have been saved the time in order to treat simultaneously.
The present invention: a kind of microcapsule that promotes osteanagenesis is made by following method:
(1) adenovirus vector carries the bone morphogenetic protein gene;
(2) cultivation of mesenchymal stem cells MSCs;
(3) carry the adenovirus vector transfection mesenchymal stem cells MSCs of skeletonization gene;
(4) microencapsulation of the mesenchymal stem cells MSCs of bone morphogenetic protein gene transfection.
The bone morphogenetic protein gene is a bone morphogenetic protein gene 2 in step (1) and the step (4).
Step (2) bone marrow is selected from rat marrow.
Flush out myeloid tissue with the alpha-MEM complete medium in the step (2).
Mesenchymal stem cells MSCs is suspended in the sodium alginate soln treated formation calcium alginate cell glue pearl in the step (4).In calcium alginate cell glue pearl suspension polylysine solution, treated formation embedding bone marrow stroma stem cell polylysine alginate microcapsule.
The disclosed a kind of microcapsule that promotes osteanagenesis of the present invention, its advantage shows: allow to use non-from the target cell of body (allosome or xenogenesis) stem cell as gene transfection, reduce like this and take from the time that the soma cell needs amplification cultivation, be used for the emergency case, and can be earlier at in-vitro screening, can guarantee the quality of cell, enlarge the range of application of cell and gene therapy.
Description of drawings
Fig. 1 shows: the microencapsulation of the mesenchymal stem cells MSCs of BMP-2 gene transfection.
Fig. 2 A shows: microencapsulation the 4th day, the expression of transgenic cell in the microcapsule is determined in external X-gal dyeing.
Fig. 2 B shows: microencapsulation the 28th day, the expression of transgenic cell in the microcapsule is determined in external X-gal dyeing.
Fig. 3 shows: the MSC microcapsule external secretion situation of transfection BMP-2.5 groups every, average.Every group of microcapsule inner cell total amount about 2.5 * 10
6/ group is incubated at 15ml alpha-MEM (containing 15% calf serum).
The specific embodiment
Below in conjunction with embodiment the present invention is further described.
Embodiment 1
The cultivation of rat bone marrow mesenchymal stem cells and Adenovirus Transfection
Get body weight 120g left and right sides SD rat, the ketamine intraperitoneal anesthesia.Under the aseptic condition of strictness, isolate the bilateral femur, with its far and near end of rongeur amputation.Flush out myeloid tissue with 10ml alpha-MEM complete medium, be inoculated in the 100mm culture dish, every ware 10ml places 37 ℃, 5%CO
2Incubator is hatched.Later half amount was changed liquid in 3 days, changed liquid after 1 week fully, changed liquid later on weekly 2 times.On 14 days, attached cell almost 90% converged, and the exhaustion culture medium with PBS flushing 2 times, adds the 1ml0.05 trypsin and contains 0.02%EDTA), place 37 ℃, 5%CO
2Incubator was hatched 5 minutes, added 9ml low sugar a-MEM complete medium with the tryptic activity that neutralizes.Blow and beat cell gently with suction pipe and make and become single cell suspension, by the cultivation of going down to posterity in 1: 3, the cell of this moment claimed first passage cell.Carrying out the 2nd passage cell with method cultivates.After the 2nd passage cell nearly 90% converges, blot culture medium, every ware adds 4ml virus working solution and spends the night (MOI=100), or does not add processing, and hatching is spent the night.The viral working solution that exhausts, every ware add 10ml alpha-MEM complete medium (FCS is through hot deactivation) to be continued to cultivate.
Embodiment 2
The microencapsulation (see figure 1) of the mesenchymal stem cells MSCs of BMP-2 gene transfection
The mesenchymal stem cells MSCs of BMP-2 gene transfection is suspended in 1.5% sodium alginate soln of filtration sterilization cell concentration 3 * 10 again
6/ ml.The cell suspending liquid of sodium alginate oozes by No. 7 blunt nosed pins of syringe pump, by large power high voltage pulse microcapsule preparing instrument (referring to utility model patent: microcapsule shaped device (patent No.: 00218100.2)), shear the drop that syringe pump oozes, and control its particle diameter.The sodium alginate Cell sap drops in gelation in the 100mM calcium chloride solution, forms calcium alginate cell glue pearl after about 5 minutes; After normal saline cleaning 2 times, calcium alginate cell glue pearl is suspended in the 0.05%-0.1% polylysine solution of filtration sterilization 5 minutes, polylysine and calcium alginate generation polyelectrolyte complex reaction film forming form embedding mesenchymal stem cells MSCs polylysine alginate microcapsule.The reuse normal saline cleans 2 times, immerses 0.15% sodium alginate soln afterwards about 5 minutes, forms another layer sodium alginate coat, cleans 2 times with normal saline, and with 55mM sodium citrate solution 20ml reaction 6 minutes, the core of microcapsule was liquefied then.After normal saline cleans, add culture medium, 37 ℃ of incubators are cultivated.
Embodiment 3
The expression (seeing Fig. 2 A, Fig. 2 B) of transgenic cell in the microcapsule is determined in external X-gal dyeing
For the effectiveness in external assessment gene therapy, the most primary is exactly whether the gene of seeing institute's transfection expresses.For this reason, we first transfection reporter gene β-gal goes into MSC, microencapsulation again, and whether observe the microcapsule inner cell can continuous release β-gal.The MSC of transfection β-gal behind microencapsulation 7 days 14,21,28 days, uses the dyeing of X-gal group respectively.At first microcapsule is moved in the 15ml centrifuge tube, fix 10 minutes with 0.5% glutaraldehyde, PBS gives a baby a bath on the third day after its birth time, adds 37 ℃ of 5%CO of X-gal dye liquor again
2Incubator spends the night.The X-gal dye liquor contains 1mg/ml X-gal, 35mM K
3Fe (CN)
6, 35mMK
3Fe (CN)
63H
2O, 2mM MgCl
2Putting into the observation of 10cm culture dish microscopically next day takes pictures.The result shows, the commentaries on classics β in the microcapsule-gal cell can be the same with the commentaries on classics β-gal cell of microcapsule not, excreting beta-gal.And at least can continuous release 28 days.
Embodiment 4
ELI SA measures the content (see figure 3) of secreting the gene recombinaton product B MP2 to capsule
When changing liquid, left and took supernatant behind the mesenchymal stem cells MSCs microencapsulation of transfection BMP-2 gene every 2 days,, measure the content of BMP2 with the ELISA method.Take out the special-purpose orifice plate of ELISA, every hole adds 100ul Assay Diluent RD-19 earlier, adds standard substance or sample again, seals with sealing, and shaking table is 2 hours under the room temperature.With 400ul Wash Buffer hole flushing, wash firmly clappers of back, repeat to wash plate 4 times, every again hole crust 200ulBMP-2Conjugate room temperature shaking table 2 hours, repeat hole flushing again 4 times, add 200ul Substrate Solution again, the lucifuge room temperature is after following 30 minutes, add 50ul StopSolution, survey OD450nm under the microplate reader behind the mixing.Simultaneously do blank with the MSC culture supernatant of untransfected BMP-2 gene.The result shows, surveys the content of BMP-2 in nearly one month time continuously.Compare obvious difference with the blank group.Showing equally can continuous release BMP-2 in the microcapsule.
Embodiment 5
The excretory BMP2 determination of activity of transgenic cell (seeing Table 1) in the microcapsule
In order to verify the activity of the endocrine BMP-2 of microcapsule, we are microcapsule (every hole microcapsule inner cell 1 * 10
6) cultivate altogether with mesenchymal stem cells MSCs, observe the conversion situation of the outer MSC of capsule.MSC microcapsule+MSC that MSC microcapsule+MSC of grouping (1) untransfected BMP-2 cultivates (2) commentaries on classics rhBMP-2 altogether cultivates altogether, row alkali phosphatase (ALP after 8 days, be osteoblastic marker protein) quantitative assay, add VitC (50 μ g/ml) in the culture medium, changed 1/3 culture medium in per 2 days, culture medium exhausted after 8 days, with Tris buffer salt solution flushing three times, the Tris that every ware adds 0.5ml 50mmol/L scrapes collection with cell, is positioned over-20 ℃ of frozen surveys fully.During detection, thaw under the room temperature, cell is measured the concentration of ALP in the lysate through ultrasonic degradation with ALP detection by quantitative test kit (Sigma).The sample number of each group is 5.The result shows that the ALP activity of mesenchymal stem cells MSCs is apparently higher than non-transfected cells microcapsule group, p＜0.05 in the Adv-hBMP-2 transfectional cell microcapsule group.
Table 1 respectively organize ALP activity (sigma unit/ml lysate) (mean ± standard deviation, IU)
| Group | Repeat number | The result |
| The MSC microcapsule of untransfected+MSC changes MSC microcapsule+MSC of rhBMP-2 | 6 6 | 42.336±0.857 52.537±1.774* |
There was a significant difference for p＜0.05 a liang group
Claims (7)
1, a kind of microcapsule that promotes osteanagenesis is made by following method:
(1) carries the adenovirus vector of bone morphogenetic protein gene;
(2) cultivation of mesenchymal stem cells MSCs;
(3) carry the adenovirus vector transfection mesenchymal stem cells MSCs of skeletonization gene;
(4) microencapsulation of the mesenchymal stem cells MSCs of bone morphogenetic protein gene transfection.
2, microcapsule according to claim 1 is characterized in that: the bone morphogenetic protein gene is the bone morphogenesis protein-2 gene in step (1) and the step (4).
3, microcapsule according to claim 1 and 2 is characterized in that: step (2) bone marrow is selected from rat marrow.
4, microcapsule according to claim 1 and 2 is characterized in that: flush out myeloid tissue with the alpha-MEM complete medium in the step (2).
5, microcapsule according to claim 1 and 2 is characterized in that: mesenchymal stem cells MSCs is suspended in the sodium alginate soln treated formation calcium alginate cell glue pearl in the step (4).
6, microcapsule according to claim 5 is characterized in that: in calcium alginate cell glue pearl suspension polylysine solution, and treated formation embedding mesenchymal stem cells MSCs polylysine alginate microcapsule.
7, the described microcapsule of claim 1 is used in preparation treatment osteopathia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101107505A CN100418582C (en) | 2005-11-25 | 2005-11-25 | Microcapsule for promoting bone regeneration and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101107505A CN100418582C (en) | 2005-11-25 | 2005-11-25 | Microcapsule for promoting bone regeneration and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1814303A true CN1814303A (en) | 2006-08-09 |
| CN100418582C CN100418582C (en) | 2008-09-17 |
Family
ID=36906732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101107505A Expired - Fee Related CN100418582C (en) | 2005-11-25 | 2005-11-25 | Microcapsule for promoting bone regeneration and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100418582C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564555B (en) * | 2009-05-27 | 2013-01-23 | 深圳市第二人民医院 | Tissue engineering bone implant and method for constructing the same |
| CN109843318A (en) * | 2016-05-24 | 2019-06-04 | 加利福尼亚大学董事会 | The growth factor nano capsule with adjustable releasability for osteanagenesis |
| CN111330072A (en) * | 2020-03-03 | 2020-06-26 | 南京鼓楼医院 | Preparation method and application of bionic porous MSCs microspheres |
| CN116769725A (en) * | 2023-08-18 | 2023-09-19 | 苏州大学附属第二医院 | RANK-overexpressing MSCs extracellular vesicle vector, and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1122520C (en) * | 2000-07-26 | 2003-10-01 | 郭德荣 | Osteanaphysis capsule for treating femoral head necrosis |
| CN1137993C (en) * | 2000-11-02 | 2004-02-11 | 上海兆安医学科技有限公司 | Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation |
-
2005
- 2005-11-25 CN CNB2005101107505A patent/CN100418582C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564555B (en) * | 2009-05-27 | 2013-01-23 | 深圳市第二人民医院 | Tissue engineering bone implant and method for constructing the same |
| CN109843318A (en) * | 2016-05-24 | 2019-06-04 | 加利福尼亚大学董事会 | The growth factor nano capsule with adjustable releasability for osteanagenesis |
| CN111330072A (en) * | 2020-03-03 | 2020-06-26 | 南京鼓楼医院 | Preparation method and application of bionic porous MSCs microspheres |
| CN111330072B (en) * | 2020-03-03 | 2021-11-23 | 南京鼓楼医院 | Preparation method and application of bionic porous MSCs microspheres |
| CN116769725A (en) * | 2023-08-18 | 2023-09-19 | 苏州大学附属第二医院 | RANK-overexpressing MSCs extracellular vesicle vector, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100418582C (en) | 2008-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bosch et al. | Osteoprogenitor cells within skeletal muscle | |
| ES2251773T3 (en) | REGENERATION OF THE CARDIAC MUSCLE USING MESENQUIMATOSE PRECURSOR CELLS. | |
| US8852571B2 (en) | Cardiac muscle regeneration using mesenchymal stem cells | |
| EP1444329B1 (en) | Stem cells that transform to beating cardiomyocytes | |
| EP2476751A1 (en) | Cardiac muscle regeneration using mesenchymal stem cells | |
| JPH10503923A (en) | Compositions and methods for stimulating proliferation and differentiation of ex vivo human fetal pancreatic cells and human adult pancreatic cells | |
| US20050244384A1 (en) | Cellular transplantation for heart regeneration | |
| US20080075750A1 (en) | Methods for producing three-dimensional tissue-engineered cardiac constructs and uses regarding same | |
| CN101014701A (en) | Cartilage and bone repair composition. | |
| KR20200018506A (en) | Compositions and Methods for Providing Cell Replacement Therapy | |
| ES2605412T3 (en) | A method to create groups of cells | |
| Day | Epithelial stem cells and tissue engineered intestine | |
| CN100418582C (en) | Microcapsule for promoting bone regeneration and its use | |
| Li et al. | Cerebrospinal Fluid Pulsation Stress Promotes the Angiogenesis of Tissue‐Engineered Laminae | |
| JPH09503662A (en) | Insulin-secreting cell line, method of making and use thereof | |
| RU2586952C1 (en) | Method of treating hepatic failure | |
| CN1878864A (en) | Insulin-expressing human islet cell line capable of reversible proliferation and use thereof | |
| US20200190475A1 (en) | Methods for identifying and isolating cardiac stem cells and methods for making and using them | |
| WO2005033268A9 (en) | Stem cells for clinical and commercial uses | |
| CN104651386A (en) | Recombinant lentiviral vector containing human osteoprotegerin gene as well as preparation method and application thereof | |
| Eschenhagen et al. | Engineered heart tissue | |
| AU2013202489A1 (en) | A method for creating cell clusters | |
| US20070178468A1 (en) | Multicellular organisms derived from normal/nondiseased and diseased mammalian tissues | |
| CN104782583A (en) | In-vitro three-dimensional cultivation model for hydatid cysts and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 200011 Shanghai manufacturing Bureau No. 639 Patentee after: SHANGHAI NINTH PEOPLE'S HOSPITAL SHANGHAI JIAOTONG University SCHOOL OF MEDICINE Address before: 200011 Shanghai manufacturing Bureau No. 639 Patentee before: University SHANGHAI 2ND MEDICAL |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20160408 Address after: 201108, No. 3, building 4299, Jin Du Road, Shanghai, Minhang District Patentee after: Shanghai Anjiu Biotechnology Co.,Ltd. Address before: 200011 Shanghai manufacturing Bureau No. 639 Patentee before: SHANGHAI NINTH PEOPLE'S HOSPITAL SHANGHAI JIAOTONG University SCHOOL OF MEDICINE |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080917 |